Catalyst

Slingshot members are tracking this event:

Phase 2 results for MGCD265 (glesatinib) in non-small cell lung cancer

Source Link:
http://www.prnewswire.com/news-releases/mirati-therapeutics-initiates-glesatinib-mgcd265-phase-2-trial-in-non-small-cell-lung-cancer-nsclc-300195598.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
MRTX
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Management Comment "In the ongoing Phase 1b dose expansion trial, glesatinib has demonstrated confirmed partial responses and significant tumor regressions in heavily pre-treated non-small cell lung cancer patients with MET or Axl gene amplification and MET mutations,"
http://www.prnewswir...
Additional Relevant Details Live Clinical Trials page:
https://www.clinical...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Mar 16, 2019
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT02544633
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Glesatinib, Mgcd265, Non-small Cell Lung Cancer, Nsclc, Open-label, Phase 2, Met Gene
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.